CAM
RNAC icon

ClariVest Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

ClariVest Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,510
Closed -$539K – 775
2021
Q4 		$539K Sell
5,510
-90
-2% -$9.68K 0.02% 425
2021
Q3 		$699K Sell
5,600
-30
-0.5% -$3.62K 0.02% 380
2021
Q2 		$706K Buy
+5,630
New +$670K 0.02% 368

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClariVest Asset Management's RNAC Position: Q1 2022 in Review

ClariVest Asset Management sold out of Cartesian Therapeutics (RNAC) in Q1 2022, closing a stake of 5,510 shares — an estimated $539K sold.

ClariVest Asset Management first reported a position in RNAC in Q2 2021 and held it in 3 quarters. The position peaked at $706K in Q2 2021. 102 funds tracked by Wall St. Rank hold RNAC as of Q1 2022.

  • ClariVest Asset Management reported no remaining Cartesian Therapeutics position as of Q1 2022 after selling out during the quarter.
  • ClariVest Asset Management sold 5,510 Cartesian Therapeutics shares in Q1 2022, an estimated $539K.
  • ClariVest Asset Management first reported a position in Cartesian Therapeutics in Q2 2021 and held it in 3 quarters.
  • ClariVest Asset Management's Cartesian Therapeutics position peaked at $706K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2022.

Based on ClariVest Asset Management's 13F filing for Q1 2022, filed 4 May 2022.